[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458371":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":20,"responsibleParty":42,"collaborators":7,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Catholic University of the Sacred Heart","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Alberto Larghi, MD","Fondazione Policlinico Universitario Agostino Gemelli","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+390630156580","alberto.larghi@yahoo.it",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":7},"Carolina Gualtieri",[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"\"Agostino Gemelli\" Hospital, Catholic University of Sacred Heart","RECRUITING","Rome","Lazio","00168","Italy","IT",{"type":30,"coordinates":31},"Point",[32,33],12.51133,41.89193,{"lat":33,"lon":32},[36,40],{"name":37,"role":15,"phone":38,"phoneExt":7,"email":39},"Guido Costamagna, MD, Prof.","+39.0630156580","gcostamagna@rm.unicatt.it",{"name":41,"role":15,"phone":7,"phoneExt":7,"email":7},"MD",{"type":12,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Guido Costamagna","Professor","100458371","genetic-microenvironmental-and-immunological-factors-in-unresectable-pancreatic-ductal-adenocarcinoma-100458371",false,"NCT05248750","Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Patients referred to EUS with FNB for suspected pancreatic cancer unresectable or metastatic based on imaging findings\n* Availability of biopsies obtained during EUS-FNB\n* Histological diagnosis of pancreatic ductal adenocarcinoma of any stage\n* Patients must be fit for chemotherapy administration\n* They have to express their willingness to be followed up at our pancreatic high volume centers\n* Age \\>18 and \\\u003C80 years\n* Able to sign informed consent\n\nExclusion Criteria:\n\n* Histological diagnoses other than pancreatic ductal adenocarcinoma\n* Pregnancy or lactation","ALL","18 Years","80 Years",{"count":55,"type":56},250,"ESTIMATED","OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherapeutic agents, making this a lethal disease. The investigators hypothesize that: (i) dissection of genetic, stromal, and immunological factors on endoscopic ultrasound fine needle biopsy (EUS-FNB) tissue samples from unresectable PDAC patients' will allow to determine prognostic factors in this patient population; (ii) treatment response and acquisition of tumor chemotherapy resistance could be related to genetic heterogeneity between the primary and metastatic sites and alteration of the molecular profile under drug' selection pressure.",[60],"Pancreas Cancer",[62,63,64],"pancreatic cancer","endoscopic ultrasound (EUS)","personalized medicine","2024-02-12",{"date":67,"type":68},"2024-02-13","ACTUAL",{"date":70,"type":68},"2021-07-22",{"date":72,"type":56},"2026-07-10",{"name":5,"class":6},1]